The effect of caffeine on attentio
- Conditions
- ANA
- Registration Number
- NL-OMON41150
- Lead Sponsor
- estec Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 72
- Age between 40-50 years (inclusive)
- Healthy male and female adults (healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical history, a complete physical examination including vital signs).
- Minimum weight of 60 kg and maximum of 85 kg.
- Average consumption of less than 150 mg of caffeine per day within the last week.
- Able to abstain from caffeine-containing foods and beverages and alcohol 24 hours prior to each testing session.
- Ability to communicate well with the investigator in the local language.
- Able to participate, willing to give written informed consent and to comply with the study restrictions.
- History or symptoms of any significant disease or condition including (but not limited to), visual, auditory, neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
- Systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg.
- History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
- History of smoking (tobacco-based products) within 12 months prior to screening.
- Positive test for drugs of abuse.
- Pregnancy (anamnesis).,
- No prescription medications, over the counter (OTC) medications, vitamin, herbal and dietary supplements will be permitted within 7 days prior to study drug administrations, or less than 5 half-lives (whichever is longer, and during the course of the study). This will be extended to substrates, inhibitors and inducers of the CYP1A2 (including broccoli, brussel sprouts, char grilled meat) and CYP3A4 (including starfruit and St John's wort). Exceptions are paracetamol (up to 4 g/day) and ibuprofen (up to 1 g/day), medications for controlling blood pressure and cholesterol, and contraceptives. Other exceptions will only be made if the rationale is discussed and clearly documented between the investigator and the sponsor.
- Subjects of the morning or eveningness type (extreme) based on a Horne and Östberg questionnaire as modified by Kerkhof.
- Participation in an investigational drug or device study within 3 months prior to screening.
- Unwillingness or inability to comply with the study protocol for any other reason.
- People working on nightshifts or regularly fly transatlantic (different time zones) flight.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary objective and outcome:<br /><br>The primary objective is to confirm whether 60mg caffeine improves sustained<br /><br>attention. The primary outcome tests will be the Rapid Visual Information<br /><br>Processing task (RVIP) and the Mackworth Clock test. RVIP was selected based on<br /><br>the scientific evaluation that deemed this type of sustained attention test as<br /><br>most sensitive to caffeine*s effects at low doses in healthy adults. The<br /><br>Mackworth Clock was selected to assess sustained attention performance over a<br /><br>long period of time.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary objectives and outcomes:<br /><br><br /><br>1. Sustained attention: RVIP and Mackworth Clocktest: number of hits<br /><br>2. Evaluate the effects of 60 mg caffeine on mood.<br /><br>3. Effect of caffeine on other CNS domains as described above.<br /><br>4. Saliva concentrations of caffeine for compliance and correlation<br /><br>relationship with attention </p><br>